TY - JOUR
T1 - Human melanoma metastases demonstrate nonstochastic site-specific antigen heterogeneity that correlates with t-cell infiltration
AU - Bartlett, Edmund K.
AU - Fetsch, Patricia A.
AU - Filie, Armando C.
AU - Abati, Andrea
AU - Steinberg, Seth M.
AU - Wunderlich, John R.
AU - White, Donald E.
AU - Stephens, Daniel J.
AU - Marincola, Francesco M.
AU - Rosenberg, Steven A.
AU - Kammula, Udai S.
PY - 2014/5/15
Y1 - 2014/5/15
N2 - Purpose: Metastasis heterogeneity presents a significant obstacle to the development of targeted cancer therapeutics. In this study, we sought to establish from a large series of human melanoma metastases whether there exists a determined pattern in tumor cellular heterogeneity that may guide the development of future targeted immunotherapies. Experimental Design: From a cohort of 1,514 patients with metastatic melanoma, biopsies were procured over a 17-year period from 3,086 metastatic tumors involving various anatomic sites. To allow specific tumor cell profiling, we used established immunohistochemical methods to perform semiquantitative assessment for a panel of prototypic melanocyte differentiation antigens (MDA), including gp100, MART-1, and tyrosinase. To gain insight into the endogenous host immune response against these tumors, we further characterized tumor cell expression of MHC I and MHC II and, also, the concomitant CD4 + and CD8 + T-cell infiltrate. Results: Tumor cell profiling for MDA expression demonstrated an anatomic site-specific pattern of antigen expression that was highest in brain, intermediate in soft tissues/lymph nodes, and lowest in visceral metastases. Hierarchical clustering analysis supported that melanoma metastases have a phylogenetically determined, rather than a stochastic, pattern of antigen expression that varies by anatomic site. Furthermore, tyrosinase expression was more frequently lost in metastatic sites outside of the brain and was uniquely correlated with both endogenous CD8 + and CD4 + T-cell infiltrates. Conclusion: Site-specific antigen heterogeneity represents a novel attribute for human melanoma metastases that should be considered in future therapy development and when assessing the responsiveness to antigen-specific immunotherapies.
AB - Purpose: Metastasis heterogeneity presents a significant obstacle to the development of targeted cancer therapeutics. In this study, we sought to establish from a large series of human melanoma metastases whether there exists a determined pattern in tumor cellular heterogeneity that may guide the development of future targeted immunotherapies. Experimental Design: From a cohort of 1,514 patients with metastatic melanoma, biopsies were procured over a 17-year period from 3,086 metastatic tumors involving various anatomic sites. To allow specific tumor cell profiling, we used established immunohistochemical methods to perform semiquantitative assessment for a panel of prototypic melanocyte differentiation antigens (MDA), including gp100, MART-1, and tyrosinase. To gain insight into the endogenous host immune response against these tumors, we further characterized tumor cell expression of MHC I and MHC II and, also, the concomitant CD4 + and CD8 + T-cell infiltrate. Results: Tumor cell profiling for MDA expression demonstrated an anatomic site-specific pattern of antigen expression that was highest in brain, intermediate in soft tissues/lymph nodes, and lowest in visceral metastases. Hierarchical clustering analysis supported that melanoma metastases have a phylogenetically determined, rather than a stochastic, pattern of antigen expression that varies by anatomic site. Furthermore, tyrosinase expression was more frequently lost in metastatic sites outside of the brain and was uniquely correlated with both endogenous CD8 + and CD4 + T-cell infiltrates. Conclusion: Site-specific antigen heterogeneity represents a novel attribute for human melanoma metastases that should be considered in future therapy development and when assessing the responsiveness to antigen-specific immunotherapies.
UR - http://www.scopus.com/inward/record.url?scp=84901049529&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901049529&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-13-2690
DO - 10.1158/1078-0432.CCR-13-2690
M3 - Article
C2 - 24647571
AN - SCOPUS:84901049529
SN - 1078-0432
VL - 20
SP - 2607
EP - 2616
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 10
ER -